drugset / Trial / NCT01408602
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
Phase 2
Unknown
300 enrolled
Molecular Research Center, Inc.
BARC Global Central Laboratory · collabBilcare Global Clinical Supplies · collabCamargo Pharmaceutical Services · collabClin Data Services · collabHarrison Clinical Research · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will treat moderate to severe rheumatoid arthritis with MRC375 (either 75 mg 3 times a day, 150 mg 3 times a day or placebo 3 times a day)in patients 18 years of age or older that can be currently on low doses of methotrexate or can stop treatment of current RA medications to enter the study. Safety of MRC375 will also be evaluated. There are up to 8 clinic visits over 24 weeks.
Timeline
- Start
- 2011-11
- Primary completion
- 2014-07
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MRC375 | Unknown | 75 mg | — |
| Subject | MRC375 | Unknown | 150 mg | — |